2:41 PM
Jul 10, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Head and neck cancer

Cell culture and mouse studies suggest BRD4 inhibitors could help treat cetuximab-resistant squamous cell carcinoma of the head and neck (SCCHN). In two human cetuximab-resistant SCCHN cell lines, cetuximab plus BRD4 knockdown or a tool compound BRD4 inhibitor...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >